XPH Quote, Financials, Valuation and Earnings

Range Cancer Therapeutics ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Range Cancer Therapeutics ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.646, which suggesting that the stock is 35.443% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 1.057, suggesting its more volatile than the S&P 500 by 5.704%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.67%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Biotechnology & Genome ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.646, which suggesting that the stock is 35.443% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.98%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.67%. Invesco Biotechnology & Genome ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Pharmaceuticals ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.646, which suggesting that the stock is 35.443% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.530, suggesting its less volatile than the S&P 500 by 46.992%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.67%. Invesco Pharmaceuticals ETF offers a yield of 1.15% to investors and pays a quarterly dividend of $0.27 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco S&P SmallCap Health Care ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco S&P SmallCap Health Care ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P SmallCap Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco S&P SmallCap Health Care ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco S&P SmallCap Health Care ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.646, which suggesting that the stock is 35.443% less volatile than S&P 500. In comparison Invesco S&P SmallCap Health Care ETF has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.736%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.67%. Invesco S&P SmallCap Health Care ETF offers a yield of 0.24% to investors and pays a quarterly dividend of $0.01 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco S&P SmallCap Health Care ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco S&P SmallCap Health Care ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco S&P SmallCap Health Care ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco S&P SmallCap Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco S&P SmallCap Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.